eMedicine Specialties > Dermatology > Papulosquamous Diseases

Psoriasis, Guttate

Author: Elma D Baron, MD, Assistant Professor of Dermatology, Case Western Reserve University, University Hospitals of Cleveland; Director of Skin Study Center, University Hospitals Research Institute; Acting Chief of Dermatology, Veterans Affairs Medical Center, Cleveland
Coauthor(s): Charles R Taylor, MD, Assistant Professor of Dermatology, Harvard Medical School; Director of Phototherapy Unit, Department of Dermatology, Massachusetts General Hospital
Contributor Information and Disclosures

Updated: Feb 1, 2007

Introduction

Background

Guttate psoriasis refers to a distinctive, acute clinical presentation of an eruption characterized by small, droplike, 1-10 mm in diameter, salmon-pink papules, usually with a fine scale (see Images 1-3). The word guttate is derived from the Latin word gutta, meaning drop. This variant primarily occurs on the trunk and the proximal extremities, but it may have a generalized distribution.

More common in individuals younger than 30 years, a history of upper respiratory infection secondary to group A beta-hemolytic streptococci (eg, Streptococcus pyogenes) often precedes the eruption by 2-3 weeks. Although recurrent episodes may occur, especially those due to pharyngeal carriage of streptococci, isolated bouts are known to occur. The sudden appearance of the papular lesions may be either the first manifestation of psoriasis in a previously unaffected individual or an acute exacerbation of long-standing plaque psoriasis. On the other hand, guttate psoriasis may be chronic and unrelated to a streptococcal infection.

Pathophysiology

The exact pathophysiologic mechanism is undetermined. The disease is believed to result from an immune reaction triggered by a previous streptococcal infection in a genetically susceptible host.

Recent studies indicate the importance of chromosome 6 in determining the resultant psoriatic phenotype. HLA-Cw*0602–positive patients are more prone to develop the guttate form. Interactions of the HLA-C with killer immunoglobulin-like receptors (KIR) on natural killer cells or natural killer T-cells can be deregulated by streptococcal infection. T lymphocytes and cytokines are believed to cause the characteristic inflammatory changes appreciated on histopathologic examination of lesional skin samples. An autoimmune phenomenon has also been postulated because some streptococcal products and components have been found to cross-react with normal human epidermis. Electron microscopic studies have shown that mast cell degranulation is an early and constant feature in the evolution of guttate psoriatic lesions.

Frequency

United States

The guttate form of psoriasis is relatively uncommon, occurring in less than 2% of the psoriatic population.

International

Surveys on the occurrence of the guttate form of eruption among patients with psoriasis range widely from 1.6-44%.

Mortality/Morbidity

Guttate psoriasis is a nonfatal eruption that either can run a limited course over several weeks to a few months or develop into the chronic plaque-type of psoriasis. Scarring is not a problem. Previously affected areas may show postinflammatory hypopigmentation or postinflammatory hyperpigmentation.

Race

Guttate psoriasis affects people of all races.

Sex

Both sexes are affected equally.

Age

Guttate psoriasis is more common in individuals younger than 30 years, and it is generally believed to be the type of psoriasis most likely to affect children and adolescents.

Clinical

History

  • In most cases, a history of an antecedent streptococcal infection, usually of the upper respiratory tract, such as pharyngitis or tonsillitis, 2-3 weeks prior to the eruption can be elicited.
  • Perianal streptococcal infections or viral infections, such as varicella, rubella, and roseola, have also been postulated as provocative factors, especially in children.
  • A positive family history of psoriasis may be present.
  • The onset of the skin lesions is often acute, with multiple papules erupting on the trunk and the proximal extremities. The lesions are often accompanied by slight pruritus.
  • Drug therapy, including biologic agents, may sometimes precipitate a guttate-type flare.

Physical

  • Examination of the skin reveals characteristic lesions consisting of multiple, discrete, 1-10 mm in diameter, droplike papules with a salmon-pink hue. A fine scale, which is usually absent in early-stage lesions, may be appreciated on the more established ones (see Image 3).
  • Beginning on the trunk and the proximal extremities, the lesions may sometimes spread to involve the face, the ears, and the scalp.
  • The palms and the soles are rarely affected.
  • Nail changes in the form of pits, ridges, and the oil-drop sign, which are characteristic of chronic psoriasis, may be absent.
  • Additional findings may include pharyngeal or perianal erythema in cases associated with acute streptococcal infections.

Causes

  • Genetic predisposition: As in other types of psoriasis, genetic predisposition seems to play an important role in the development of an acute guttate psoriasis flare. Compared with control populations, a significant excess of HLA-BW17 has been found in patients with guttate psoriasis. Others have found an increase in HLA-B13 positivity. Moreover, the inability to produce normal amounts of antibody to streptolysin-O by HLA-B13–positive individuals might explain the high prevalence in guttate psoriasis. Interestingly, an increased prevalence of HLA-CW6 has also been found. Thus far, psoriasis is the only disease associated with HLA-C gene expression. Recently, proteomic studies have been able to demonstrate that guttate psoriasis and chronic plaque psoriasis are phenotypically distinguishable in their protein expression patterns.
  • Streptococcal infection
    • The association of guttate psoriasis with streptococcal infection has been recognized for more than 50 years. As many as 80% of patients with guttate psoriasis have clinical or laboratory evidence of streptococcal infection, usually in the form of tonsillopharyngitis. Aside from group A streptococci, groups C and G streptococci have also been related to guttate psoriasis.
    • The ability of the streptococcal organism to trigger an eruption is not serotype specific. The serotypes present in patients with guttate psoriasis are similar to those seen in the general population. A number of cases of guttate psoriasis in children have also been triggered by streptococcal perianal cellulitis. Presumably, absorption of streptococci by-products produced by the streptococci occurs across the rectal mucosa, as with pharyngeal infections. Unfortunately, although the association is definite, details regarding the exact mechanism by which streptococcal infection influences the actual formation of the psoriatic lesions are still largely theoretical.
  • Role of T lymphocytes
    • Histologic studies of early-stage psoriatic skin lesions revealed that the activation of T lymphocytes, endothelial cells, and macrophages precedes epidermal proliferation. The increased proliferation of the epidermal layer characteristic of psoriasis might be induced by activated T lymphocytes via the production of cytokines. Indeed, group A streptococcal antigen-specific T lymphocytes, which secrete high levels of gamma interferon, can be consistently isolated from guttate psoriatic skin lesions.
    • Consistent with the role of T lymphocytes is the concept of superantigenic stimulation by certain streptococcal components or products. Examples of superantigens produced by group A beta-hemolytic streptococci are streptococcal pyogenic exotoxins (SPE) types A, B, and C; a 22-kd pepsin fragment of M type-5 protein; S pyogenes– derived cytoplasmic membrane-associated protein (CAP); and secretion-type CAP (SCAP).
    • In general, unlike a conventional peptide antigen, a superantigen stimulates T cells almost solely through the beta variable (Vß) portion of the T-cell receptor and induces an expansion of both CD4+ and CD8+ T cells. Therefore, an increased representation of Vß2+ T lymphocytes, such as that in both the epidermis and the dermis of guttate psoriatic lesions, compared with that of lymphocytes from the peripheral blood of the same patients and lymphocytes in normal skin strongly suggests that T-cell stimulation by a superantigen is probably involved.
  • Role of autoantibodies
    • Immunoblotting has demonstrated intense antistreptococcal antibody activity in the sera of patients with guttate psoriasis. Immunoglobulin G (IgG) antibodies against 3 different S pyogenes proteins, namely, a 60-, a 70-, and a 14-kd antigen, have been identified. Indirect immunofluorescence studies of these antibodies showed that they only react with autologous skin in patients with guttate psoriasis and not with normal skin or lesional skin from patients who do not have psoriasis.
    • Autoantibodies in psoriatic sera may recognize certain structures in the transformed keratinocytes of affected psoriatic skin. These autoantibodies cross-react with streptococcal antigens, and it has been demonstrated on immunofluorescent microscopy by using a monoclonal antibody (mAb 111-15504) to group A streptococci, which does not cross-react with antigens in normal human skin. These antigens were associated with class 1M protein and were mostly concentrated in the dermal papillae around the capillaries and inside the cells of the epidermal basal layer.

More on Psoriasis, Guttate

Overview: Psoriasis, Guttate
Differential Diagnoses & Workup: Psoriasis, Guttate
Treatment & Medication: Psoriasis, Guttate
Follow-up: Psoriasis, Guttate
Multimedia: Psoriasis, Guttate
References

References

  1. Baker BS, Bokth S, Powles A, et al. Group A streptococcal antigen-specific T lymphocytes in guttate psoriatic lesions. Br J Dermatol. May 1993;128(5):493-9. [Medline].

  2. Baughman RD. Search for Streptococcus. Arch Dermatol. Jan 1992;128(1):103. [Medline].

  3. Borroni G, Vignati G, Zaccone C, et al. Photofibrosis: a further histopathological change induced by PUVA therapy via the mast cell in guttate psoriasis. Preliminary report. Acta Derm Venereol Suppl (Stockh). 1994;186:159-61. [Medline].

  4. Brody I. Dermal and epidermal involvement in the evolution of acute eruptive guttate psoriasis vulgaris. J Invest Dermatol. May 1984;82(5):465-70. [Medline].

  5. Carlén LM, Sánchez F, Bergman AC, et al. Proteome analysis of skin distinguishes acute guttate from chronic plaque psoriasis. J Invest Dermatol. Jan 2005;124(1):63-9. [Medline].

  6. Chalmers RR, O''Sullivan T, Owen CC, Griffiths CC. A systematic review of treatments for guttate psoriasis. Br J Dermatol. Dec 2001;145(6):891-4. [Medline].

  7. England RJ, Strachan DR, Knight LC. Streptococcal tonsillitis and its association with psoriasis: a review. Clin Otolaryngol. Dec 1997;22(6):532-5. [Medline].

  8. Farber EM, Nall L. Epidemiology: Natural history and genetics. In: Roenigk H, Maibach H, eds. Psoriasis. 3rd ed. Marcel & Dekker;1998.

  9. Fry L, Powles AV, Corcoran S, et al. HLA Cw*06 is not essential for streptococcal-induced psoriasis. Br J Dermatol. May 2006;154(5):850-3. [Medline].

  10. Goiriz R, Dauden E, Perez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol. Dec 14 2006;[Medline].

  11. Henderson CA, Highet AS. Acute psoriasis associated with Lancefield Group C and Group G cutaneous streptococcal infections. Br J Dermatol. Apr 1988;118(4):559-61. [Medline].

  12. Holm SJ, Sakuraba K, Mallbris L, et al. Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J Invest Dermatol. Oct 2005;125(4):721-30. [Medline].

  13. Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol. Dec 1996;21(6):546-7. [Medline].

  14. Honig PJ. Guttate psoriasis associated with perianal streptococcal disease. J Pediatr. Dec 1988;113(6):1037-9. [Medline].

  15. Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest. Nov 1995;96(5):2106-12. [Medline].

  16. Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?. Arch Dermatol. Jun 1996;132(6):717-8. [Medline].

  17. Perez-Lorenzo R, Zambrano-Zaragoza JF, Saul A, et al. Autoantibodies to autologous skin in guttate and plaque forms of psoriasis and cross-reaction of skin antigens with streptococcal antigens. Int J Dermatol. Jul 1998;37(7):524-31. [Medline].

  18. Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report. J Am Acad Dermatol. May 1986;14(5 Pt 1):761-4. [Medline].

  19. Talanin NY, Shelley WB, Raeder R, et al. Detection of streptococcal class I M protein in psoriasis by confocal immunofluorescent microscopy. Acta Derm Venereol. May 1997;77(3):175-80. [Medline].

  20. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. Jan 1992;128(1):39-42. [Medline].

  21. Thappa DM, Laxmisha C. Suit PUVA as an effective and safe modality of treatment in guttate psoriasis. J Eur Acad Dermatol Venereol. Oct 2006;20(9):1146-7. [Medline].

  22. Toussaint S, Kamino H. Noninfectious, erythematous, papular and squamous diseases. In: Lever's Histopathology of the Skin. 8th ed. Lippincott-Raven Publishers;1997.

  23. Villeda-Gabriel G, Santamaria-Cogollos LC, Perez-Lorenzo R, et al. Recognition of Streptococcus pyogenes and skin autoantigens in guttate psoriasis. Arch Med Res. Summer 1998;29(2):143-8. [Medline].

  24. Williams RC, McKenzie AW, Roger JH, Joysey VC. HL-A antigens in patients with guttate psoriasis. Br J Dermatol. Aug 1976;95(2):163-7. [Medline].

  25. Wilson AG, Clark I, Heard SR, et al. Immunoblotting of streptococcal antigens in guttate psoriasis. Br J Dermatol. Feb 1993;128(2):151-8. [Medline].

Further Reading

Keywords

guttate psoriasis, perianal streptococcal infection, Streptococcus pyogenes, S pyogenes, upper respiratory infection

Contributor Information and Disclosures

Author

Elma D Baron, MD, Assistant Professor of Dermatology, Case Western Reserve University, University Hospitals of Cleveland; Director of Skin Study Center, University Hospitals Research Institute; Acting Chief of Dermatology, Veterans Affairs Medical Center, Cleveland
Elma D Baron, MD is a member of the following medical societies: American Academy of Dermatology, American Society for Photobiology, Photomedicine Society, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Coauthor(s)

Charles R Taylor, MD, Assistant Professor of Dermatology, Harvard Medical School; Director of Phototherapy Unit, Department of Dermatology, Massachusetts General Hospital
Charles R Taylor, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Laser Medicine and Surgery, Massachusetts Medical Society, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Medical Editor

Mark G Lebwohl, MD, Chairman, Department of Dermatology, Mount Sinai School of Medicine
Mark G Lebwohl, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Abbott Laboratories Honoraria Consulting; Actelion Honoraria Consulting; Amgen Honoraria Consulting; Astellas Honoraria Consulting; Basilea Honoraria Consulting; Briston-Myers Squibb Honoraria Consulting; Celtic Pharma  Other; Centocor Honoraria Consulting; Chattem Honoraria Other; DermiPsor Honoraria Consulting

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: 3M Pharmaceutical Grant/research funds Other; Graceway Pharmaceuticals Grant/research funds Other

Managing Editor

Christen M Mowad, MD, Assistant Professor, Department of Dermatology, Geisinger Medical Center
Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.